Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for Alvelestat in AATD-LD
核心洞察
Sentynl Therapeutics (搜索) and Mereo BioPharma have entered into an option and license agreement granting Sentynl U.S. commercial rights to alvelestat, a potential first-in-class oral neutrophil elastase (搜索) inhibitor for AATD-LD.
Mereo will receive an upfront option fee and, upon option exercise, up to $40 million in upfront and R&D payments until NDA filing, plus double-digit tiered royalties on U.S. net sales.
Alvelestat is being readied for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies, with initiation potentially in early 2027.
Sentynl Therapeutics (搜索), Inc., a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, and Mereo BioPharma Group plc have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (搜索) (AATD-LD). Announced on August 11, 2026, the agreement positions alvelestat — a novel, oral small-molecule neutrophil elastase (搜索) inhibitor — as a potential first-in-class oral therapy for this rare, progressive genetic lung disease.
Under the terms of the agreement, Sentynl receives the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, while Mereo retains commercial rights in the rest of the world. Sentynl also secures global manufacturing rights for the asset. Mereo will receive a non-refundable option fee and, upon exercise of the option, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, along with double-digit tiered royalties on U.S. net sales.
A Differentiated Mechanism for an Unmet Need
Alvelestat is designed to specifically inhibit neutrophil elastase (搜索), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat can access both cell-bound and soluble elastase and effectively penetrate lung tissue. Its safety and tolerability profile has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19, and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.
The drug has received Orphan Drug Designation for AATD-LD from both the European Commission and the U.S. Food and Drug Administration, as well as Fast Track designation from the FDA.
Phase 3 Readiness and Collaboration
Mereo has been preparing alvelestat for a global Phase 3 study, supported by positive efficacy data from two Phase 2 studies. During the option period, the two companies will collaborate to refine the global Phase 3 study design and advance manufacturing. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed, with the Phase 3 program potentially initiating in early 2027.
“We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. “We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat.”
Matt Heck, Chief Executive Officer of Sentynl Therapeutics (搜索), emphasized the unmet need: “For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat.”
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, added: “This partnership marks a pivotal moment for Sentynl's rare disease strategy. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.”
Disease Background
AATD is a rare genetic disease resulting from a deficiency of the alpha-1 antitrypsin protein, which normally protects the lungs against damaging enzymes released during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease characterized by severe shortness of breath, chronic cough, and sputum production with susceptibility to acute exacerbations. Affected individuals may also develop asthma and bronchiectasis. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000 to 80,000 individuals.
Strategic Fit and Portfolio Expansion
The agreement expands Sentynl's rare disease portfolio with a late-stage asset that complements its existing commercial infrastructure. Mereo BioPharma, which focuses on innovative therapeutics for rare diseases, maintains a pipeline that also includes setrusumab for osteogenesis imperfecta and vantictumab for autosomal dominant osteopetrosis type 2. The partnership allows Mereo to advance alvelestat toward registration while retaining ex-U.S. commercial rights and benefiting from Sentynl's U.S. commercialization capabilities.